Harmony Biosciences (NASDAQ:HRMY) CFO Sells $752,919.12 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 20,961 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $35.92, for a total transaction of $752,919.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Harmony Biosciences Stock Down 0.9%

NASDAQ:HRMY traded down $0.31 during trading hours on Tuesday, reaching $35.91. 719,898 shares of the company traded hands, compared to its average volume of 525,630. The business’s 50-day moving average price is $36.92 and its two-hundred day moving average price is $34.09. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $2.07 billion, a P/E ratio of 11.29, a P/E/G ratio of 0.38 and a beta of 0.84. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.93.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. The firm had revenue of $239.46 million for the quarter, compared to analysts’ expectations of $222.68 million. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on HRMY. Wall Street Zen raised Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Mizuho raised their price target on shares of Harmony Biosciences from $39.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, December 1st. UBS Group decreased their price objective on shares of Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Oppenheimer restated an “outperform” rating and issued a $62.00 target price on shares of Harmony Biosciences in a report on Monday, November 24th. Finally, Truist Financial cut their target price on shares of Harmony Biosciences from $48.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.25.

Institutional Trading of Harmony Biosciences

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its holdings in Harmony Biosciences by 4,102.4% in the 4th quarter. SG Americas Securities LLC now owns 961,667 shares of the company’s stock worth $35,986,000 after buying an additional 938,783 shares during the period. Boston Partners purchased a new position in shares of Harmony Biosciences in the second quarter valued at about $19,398,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Harmony Biosciences by 127.6% in the second quarter. Arrowstreet Capital Limited Partnership now owns 906,909 shares of the company’s stock worth $28,658,000 after acquiring an additional 508,498 shares during the period. UBS Group AG grew its position in shares of Harmony Biosciences by 213.3% during the third quarter. UBS Group AG now owns 503,081 shares of the company’s stock worth $13,865,000 after purchasing an additional 342,505 shares in the last quarter. Finally, Nomura Holdings Inc. grew its position in shares of Harmony Biosciences by 382.3% during the second quarter. Nomura Holdings Inc. now owns 422,919 shares of the company’s stock worth $13,364,000 after purchasing an additional 335,237 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.